Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: Insights from the NEFIGAN trial

Nefecon is the first approved treatment for patients with IgA nephropathy (IgAN) at high risk of progression to kidney failure (accelerated approval: US Food and Drug Administration [FDA]; conditional approval: European Medicines Agency [EMA]).1-3 Nefecon delivers budesonide, in a targeted formulation, to the gut-associated lymphoid tissue (GALT) of the ileum directly addressing immune dysregulation within this Peyer ’s patches (PP)-rich area of the GALT and downregulating the local production of the polymeric poorly O-galactosylated form of immunoglobulin (Ig)A1 or galactose-deficient IgA1 (Gd-IgA1) and generation of pathogenic IgA-containing immune complexes (IgA-IC).

Source: Kidney International - November 24, 2023 Category: Urology & Nephrology Authors: David Wimbury, Masahiro Muto, Jasraj S. Bhachu, Katrin Scionti, Jeremy Brown, Karen Molyneux, Claudia Seikrit, Dita Maixnerov á, Laura Pérez-Alós, Peter Garred, Jürgen Floege, Vladimír Tesař, Bengt Fellstrom, Rosanna Coppo, Jonathan Barratt Tags: research letter Source Type: research